necitumumab,osimertinib
nippon kayaku,astrazeneca,eli lilly
['sclc', 'osimertinib', 'nsclc', 'necitumumab']
several studies exploring #egfr exon 20 insertion nsclc at #asco22. combination of osimertinib and necitumumab showed rr 16%, mpfs 6.9m in this subset. 
Director of Thoracic Oncology & Developmental Therapeutics @LombardiCancer, Associate Professor @Georgetown University #LCSM #HereWeGo #ITYSL He/Him